methyl (2R)-2-aminopentanoate | 21685-17-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl (2R)-2-aminopentanoate
• 英文别名: (R)-(-)-norvaline methyl ester；D-norvaline methyl ether；D-norvaline methyl ester；norvaline methyl ester；(R)-Methyl 2-aminopentanoate
• CAS: 21685-17-6
• 化学式: C₆H₁₃NO₂
• 分子量: 131.175
• InChiKey: VXGRMCZTYDXKQW-RXMQYKEDSA-N

物化性质

• 沸点：
  152.3±13.0 °C(Predicted)
• 密度：
  0.970±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl (2R)-2-aminopentanoate 在 吡啶 、 碘苯二乙酸 、 碘 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 29.0h， 生成 (R)-methyl 1-tosylpyrrolidine-2-carboxylate
  参考文献：
  名称：

  Chemoselective Intramolecular Functionalization of Methyl Groups in Nonconstrained Molecules Promoted by N-Iodosulfonamides

  摘要：

  Mechanistic evidence observed in Hofmann-Loffler-Freytag-type reactions has been crucial to achieve the chemoselective functionalization of methyl groups under mild conditions. Radical-mediated methyl iodination and subsequent oxidative deiodination are the key steps in this functionalization, where iodine chemistry has a pivotal role on the formation of the C-N bond. The concepts of single hydrogen atom transfer (SHAT) and multiple hydrogen atom transfer (MHAT) are introduced to describe the observed chemoselectivity.

  DOI：

  10.1021/acs.orglett.5b00866
• 作为产物：
  描述：

  D-正缬氨酸 在 氯化亚砜 作用下， 反应 20.25h， 以95%的产率得到methyl (2R)-2-aminopentanoate
  参考文献：
  名称：

  WO2007/1015

  摘要：

  公开号：

文献信息

• Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors
  作者：Shuai Liu、Hailemichael O. Yosief、Lingling Dai、He Huang、Gagan Dhawan、Xiaofeng Zhang、Alex M. Muthengi、Justin Roberts、Dennis L. Buckley、Jennifer A. Perry、Lei Wu、James E. Bradner、Jun Qi、Wei Zhang

  DOI：10.1021/acs.jmedchem.8b00765

  日期：2018.9.13

  inhibition of polo-like kinase 1 (PLK1) and BRD4 bromodomain by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are implicated. Compound 23 has been found to be a potent dual kinase-bromodomain inhibitor (BRD4-BD1 IC50 = 28 nM, PLK1 IC50 = 40 nM). Compound 6 was found to be the most selective PLK1 inhibitor over BRD4

  通过单个分子同时抑制 Polo 样激酶 1 (PLK1) 和 BRD4 溴结构域可能会导致开发出针对 PLK1 和 BRD4 涉及的多种疾病的有效治疗策略。化合物 23 被发现是一种有效的双激酶-溴结构域抑制剂（BRD4-BD1 IC50 = 28 nM，PLK1 IC50 = 40 nM）。发现化合物 6 是我们系列中相对于 BRD4 最具选择性的 PLK1 抑制剂（BRD4-BD1 IC50 = 2579 nM，PLK1 IC50 = 9.9 nM）。 23 和 BRD4-BD1/PLK1 以及 6 的分子对接研究证实了生化测定结果。
• Polycyclic Azetidines and Pyrrolidines via Palladium-Catalyzed Intramolecular Amination of Unactivated C(sp3)–H Bonds
  作者：Jie Zhao、Xiao-Jing Zhao、Pei Cao、Ji-Kai Liu、Bin Wu

  DOI：10.1021/acs.orglett.7b02339

  日期：2017.9.15

  A novel strategy to construct complex polycyclic nitrogen-containing heterocycles from aliphatic amines via picolinamide-assisted palladium-catalyzed C–H bond activation reaction was reported. The reaction exhibits broad substrate scope for the synthesis of various azabicyclic scaffolds, including azetidines and tropane-class alkaloids. Application of this method to naturally occurring (−)-cis-myrtanylamine

  据报道，有一种新的策略可以通过吡啶甲酰胺辅助的钯催化的C–H键活化反应从脂肪族胺中构建复杂的多环含氮杂环。该反应显示出广泛的底物范围，可用于合成各种氮杂双环支架，包括氮杂环丁烷和托烷类生物碱。该方法在天然存在的（-）-顺式-二甲基乙胺中的应用，这是前所未有的碳-碳键活化，其中涉及的电子对引发了环钯片段的分子内“ S N 2样”置换。第三中心，描述。
• Exciton-Coupled Circular Dichroism Characterization of Monotopically Binding Guests in Host−Guest Complexes with a Bis(zinc porphyrin) Tweezer
  作者：Sandra Olsson、Clara Schäfer、Magnus Blom、Adolf Gogoll

  DOI：10.1002/cplu.201800564

  日期：2018.12

  A stiff-stilbene-linked bisporphyrin tweezer with inherent helicity was used for exciton-coupled circular dichroism (ECCD) characterization of a series of monotopically binding amine guest molecules. CD signals were observed for a variety of monoamines at relatively low tweezer/amine (host/guest) ratios between 1 : 10 to 1 : 70. For the amines producing the most intense CD signals, a binding stoichiometry

  具有固有螺旋度的刚性-苯乙烯连接的双卟啉镊子用于一系列单位结合的胺客体分子的激子偶联圆二色性（ECCD）表征。在相对较低的镊子/胺（主体/客体）比例为1:10至1:70的范围内，观察到各种单胺的CD信号。对于产生最强CD信号的胺，发现其化学计量比为1：2。一个可能的解释是复合体中访客与访客之间的相互作用。CD信号强度与来宾之间可能的非共价结合强度之间的相关性支持了这一点，可以将其分为三组，分别显示无，中度和强反应。这种合理化的进一步支持来自分子建模。
• 6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
  申请人：SANOFI

  公开号：US20130085128A1

  公开（公告）日：2013-04-04

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4、R5、R6和R7如下所示。式I的化合物是激酶抑制剂，适用于治疗与糖尿病及糖尿病并发症相关的疾病，如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变等。此外，本发明还涉及式I的化合物的用途，特别是作为药物中的活性成分以及包含它们的药物组合物。
• [EN] 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'AMIDE D'ACIDE 6-(4-HYDROXYPHÉNYL)-3-ALKYL-1H-PYRAZOLO[3,4-B] PYRIDINE-4-CARBOXYLIQUE UTILISÉS COMME INHIBITEURS DE KINASE
  申请人：SANOFI SA

  公开号：WO2013045413A1

  公开（公告）日：2013-04-04

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula (I), in which R1, R2, R3, R4, R5, R6 and R7 are defined as indicated below. The compounds of the formula (I) are protein kinase C (PKC) inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式(I)的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4、R5、R6和R7如下所示。式(I)的化合物是蛋白激酶C（PKC）抑制剂，并且对于治疗与糖尿病和糖尿病并发症相关的疾病，例如糖尿病肾病、糖尿病神经病和糖尿病视网膜病变等，非常有用。此外，本发明还涉及使用该式化合物，特别是作为药物中的活性成分，以及包含它们的制药组合物。